RonaldJBuckanovichMD

Oncology • Pittsburgh, PA

Hematologic Oncology

Physician

Join to view full profile

Dr. Buckanovich is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Buckanovich's full profile

Already have an account?

Office
5115 Centre Avenue
B1 Floor Cancer Recp C
Pittsburgh, PA 15232
Phone(734) 647-8906
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology/Oncology, 2001 - 2004
University of Pennsylvania Health SystemResidency, Internal Medicine, 1998 - 2001
Weill Cornell Medical College of Cornell UniversityClass of 1998

Certifications & Licensure

MI State Medical License 2006 - 2019
PA State Medical License 1999 - 2022
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Elected Member The American Society for Clinical Investigation, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Start of enrollment: 2013 Apr 01Cristea, M.C.,Garcia, A.A.,Scudder, S.A.,Koehler, S.C.,Fleming, G.F.,Wade, J.L.,Hurteau, J.A.,Matei, D.E.,Buckanovich, R.J.,Morris, R.T.,Jain, A.,Edwards, R.P.,Ghatage, P.,Tonkin, K.S.,Oza, A.M.,Hirte, H....
A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Start of enrollment: 2011 Oct 01Buckanovich, R.J.
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Mar 01Houston, N.,Liu, J.,Lundquist, C.,Whalen, C.
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Ronald Buckanovich, M.D., Ph.D.

Publications & Presentations

PubMed

Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis
Huihui Fan, Huda Atiya, Yeh Wang, Thomas R. Pisanic, Tza-Huei Wang, Ie Ming Shih, Kelly Foy, Leonard Frisbie, Ronald J. Buckanovich, Alison A. Chomiak, Rochelle L. Tie...> ;Cell Reports. 2020 Dec 8
Regulation and pharmacological targeting of RAD51 in cancer.
Grundy, M. K., Buckanovich, R. J., Bernstein, K. A.> ;NAR cancer. 2020 Oct 6
Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling.
Raghavan, S., Snyder, C. S., Wang, A., McLean, K., Zamarin, D., Buckanovich, R. J., Mehta, G.> ;Cancers. 2020 Jul 31
Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer.
Brown, J. R., Chan, D. K., Shank, J. J., Griffith, K. A., Fan, H., Szulawski, R., Yang, K., Reynolds, R. K., Johnston, C., McLean, K., Uppal, S., Liu, J. R., Cabrera, ...> ;JCI insight. 2020 May 6
NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer.
Cole, A. J., Iyengar, M., Panesso-Gómez, S., O'Hayer, P., Chan, D., Delgoffe, G. M., Aird, K. M., Yoon, E., Bai, S., Buckanovich, R. J.> ;JCI insight. 2020 Mar 18
An evolving paradigm of cancer stem cell hierarchies: therapeutic implications.
Alexander J. Cole, Adetunji P. Fayomi, Vivian I. Anyaeche, Shoumei Bai, Ronald J. Buckanovich> ;Theranostics. 2020 Feb 10
Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma.
Samanta, S., Tamura, S., Dubeau, L., Mhawech-Fauceglia, P., Miyagi, Y., Kato, H., Lieberman, R., Buckanovich, R. J., Lin, Y. G., Neamati, N.> ;Scientific reports. 2020 Feb 9
CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary.
Bai, S., Zhu, W., Coffman, L., Vlad, A., Schwartz, L. E., Elishaev, E., Drapkin, R., Buckanovich, R. J.> ;Cancers. 2019 Nov 7
No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.
Buckanovich, R. J., Rustin, G., Uppal, S., Olawaiye, A. B., Kelley, J. L., Berger, J. L., Landen, C. N.> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Aug 27
Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.
Rashidi, M. R., Mehta, P., Bregenzer, M., Raghavan, S., Fleck, E. M., Horst, E. N., Harissa, Z., Ravikumar, V., Brady, S., Bild, A., Rao, A., Buckanovich, R. J., Mehta...> ;Neoplasia (New York, N.Y.). 2019 Jul 13
The double edge sword of fibrosis in cancer.
Chelsea Chandler, Tianshi Liu, Ronald J. Buckanovich, Lan G. Coffman> ;Translational Research. 2019 Jul 1
Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.
Madariaga, A., Rustin, G. J., Buckanovich, R. J., Trent, J. C., Oza, A. M.> ;American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2019 May 18
A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
Chefetz, I., Grimley, E., Yang, K., Hong, L., Vinogradova, E. V., Suciu, R., Kovalenko, I., Karnak, D., Morgan, C. A., Chtcherbinine, M., Buchman, C., Huddle, B., Barr...> ;Cell reports. 2019 Mar 14
A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs.
Nagaraj, A. B., Joseph, P., Ponting, E., Fedorov, Y., Singh, S., Cole, A., Lee, W., Yoon, E., Baccarini, A., Scacheri, P., Buckanovich, R., Adams, D. J., Drapkin, R., ...> ;Stem cell reports. 2019 Jan 11
Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma.
Coffman, L. G., Pearson, A. T., Frisbie, L. G., Freeman, Z., Christie, E., Bowtell, D. D., Buckanovich, R. J.> ;Stem cells (Dayton, Ohio). 2018 Oct 26
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
McLean, K., Tan, L., Bolland, D. E., Coffman, L. G., Peterson, L. F., Talpaz, M., Neamati, N., Buckanovich, R. J.> ;Oncogene. 2018 Oct 12
Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.
Huddle, B. C., Grimley, E., Buchman, C. D., Chtcherbinine, M., Debnath, B., Mehta, P., Yang, K., Morgan, C. A., Li, S., Felton, J., Sun, D., Mehta, G., Neamati, N., Bu...> ;Journal of medicinal chemistry. 2018 Sep 18
CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.
Iyengar, M., O'Hayer, P., Cole, A., Sebastian, T., Yang, K., Coffman, L. G., Buckanovich, R. J.> ;Oncotarget. 2018 Apr 13
Sampling from single-cell observations to predict tumor cell growth in-vitro and in-vivo.
Alexander T. Pearson, Patrick N. Ingram, Shoumei Bai, Patrick O'Hayer, Jaehoon Chung, Euisik Yoon, Trachette L. Jackson, Ronald J. Buckanovich> ;Oncotarget. 2017 Nov 25
Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages.
Penn, C. A., Yang, K., Zong, H., Lim, J., Cole, A., Yang, D., Baker, J. R., Goonewardena, S. N., Buckanovich, R. J.> ;Molecular cancer therapeutics. 2017 Nov 15
Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer.
Soma Samanta, Shuzo Tamura, Louis Dubeau, Paulette Mhawech-Fauceglia, Yohei Miyagi, Hisamori Kato, Rich W. Lieberman, Ronald J. Buckanovich, Yvonne G. Lin, Nouri Neamati> ;Oncotarget. 2017 Oct 7
Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.
Andrea Facciabene, Francesco De Sanctis, Stefano Pierini, Edimara S. Reis, Klara Balint, John G. Facciponte, Jens Rueter, Masahiro Kagabu, Paola Magotti, Evripidis Lan...> ;OncoImmunology. 2017 Aug 22
3 citations
Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan, S., Mehta, P., Ward, M. R., Bregenzer, M. E., Fleck, E. M., Tan, L., McLean, K., Buckanovich, R. J., Mehta, G.> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 18
4 citations
A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
Vergote, I. B., Smith, D. C., Berger, R., Kurzrock, R., Vogelzang, N. J., Sella, A., Wheler, J. J., Lee, Y., Foster, P. G., Weitzman, R., Buckanovich, R. J.> ;European journal of cancer (Oxford, England : 1990). 2017 Jul 30
EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells
Shoumei Bai, Patrick Ingram, Yu Chih Chen, Ning Deng, Alexander T. Pearson, Yashar S. Niknafs, Patrick O’Hayer, Yun Wang, Zhong Yin Zhang, Elisa Boscolo, Joyce Bischof...> ;Cancer Research. 2016 Nov 1
Join now to see all

Lectures

Changing the Perspective for ""Successful"" Maintenance Therapy
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian CancerOctober 29, 2019 21:33
Targeting Stem-like Cells Could Prevent Ovarian Cancer RecurrenceMarch 12, 2019 17:49
Gynecology | U P D a T E S I N |March 10, 2018 10:37
Join now to see all

Grant Support

Targeting Ovarian Tumor Associated Myeloid Cells With Nanoparticles TherapeuticsNational Cancer Institute2012
Using Embryonic Stem Cells To Re-Create A Human Tumor Microenvironment To DevelopOffice Of The Director, National Institutes Of Health2008